Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,636.36
(
2.00%
)
US TECH 100
23,770.40
(
2.10%
)
Dow Jones
46,585.22
(
2.21%
)
Brent Oil
95.75
(
-11.45%
)
Bitcoin
70,901.38
(
4.52%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

oc631

Send PM Follow Ignore
Followers 15
Posts 1749
Boards Moderated 0
Alias Born 08/12/2007

oc631

Re: DewDiligence post# 164497

Thursday, 07/25/2013 10:06:35 PM

Thursday, July 25, 2013 10:06:35 PM

Post# of 257269

GILD expects GT3 labeling to be the focus of Sofosbuvir's FDA advisory panel on 10/25/13, according to today's CC.





The cost to the healthcare system for retreating patients would be huge if Sofo/Riba is labeled for GT3. This should be a fun advisory panel.


I didn't get to listen to the call yet. What stands out in the PR is how well the sofosbuvir/ledipasvir combo is working without riba.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today